Nevertheless, while beneficial in the early phase of infection when the antiviral activity of IFNs limited SARS-CoV-2 replication, a detrimental response may be elicited in late stages, when uncontrolled IFN response could drive inflammatory lung pathology. This evidence concerns the gene IFNA1 and infection.